Indo Us Biotech growth over the years

·FMCG & RetailChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+6.4%
EBITDA−10.2%
Net Income−19.3%
EPS (adj.)−19.3%
Total Assets+36.1%
Total Equity+17.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹64.99

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹130 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+6.4
EBITDA-10.2
Net Income-19.3
EPS (adj.)-19.3
Total Assets+36.1
Total Equity+17.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.